Simcere Pharmaceutical Receives First Generic Biapenem Certificate
This article was originally published in PharmAsia News
Simcere Pharmaceutical Group's first generic biapenem drug has received new drug certificate and production approval from China's State FDA. A newly launched generic drug enjoys a four-year assessment grace period during which SFDA declines applications of similar chemical compounds or drug administration routes whose R&D has not entered into clinical stages. Biapenem, like Merck's Tienam and Dainippon Sumitomo's Mepem, comes under carbapenem antibiotics. The drugs have a 1.6 billion yuan market in China, with 30 percent annual growth over the past three years. Simcere believes that the biapenem's approval will enhance the firm's long-term strategy of focusing on first-to-market anti-infection generic drugs. (Click here for more - Chinese Language)
You may also be interested in...
Netherlands' Medicines Evaluation Board says the safety of paracetamol is "not up for debate" after a media investigation reported contamination of the drug with a possible human carcinogen.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.